This combinatorial strategy also reshaped the tumor immune landscape by increasing activated NK cells, elevating Granzyme B expression in CD4<sup>+</sup> T cells, and decreasing immunosuppressive M-MDSCs expressing CD39, CD38, and CD73. The gene discussed is ENTPD1; the disease is neoplasm.